Physician profile
Samuel Miller
NPI 1851352942
$179,361.51
in general payments reported to CMS, 2019-2025
50 companies · $7,713 in 2025
The $7,713 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,843 · 2020: $10K · 2021: $19K · 2022: $71K · 2023: $45K · 2024: $21K · 2025: $7,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Food and Beverage: $4,933 · Travel and Lodging: $2,440 · Consulting Fee: $450 · Education: $13.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,256.25 |
| Food and Beverage | $4,933.30 |
| Travel and Lodging | $2,439.64 |
| Consulting Fee | $450.00 |
| Education | $13.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $152,410.17 | 2021-2025 | |
| Allergan, INC. | $12,390.45 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,853.32 | 2019-2025 | |
| Biogen, INC. | $1,825.27 | 2019-2025 | Tysabri, Vumerity, Tysabri |
| Lilly USA, LLC | $896.47 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Teva Pharmaceuticals USA, INC. | $843.09 | 2019-2024 | Austedo Xr, Austedo |
| Amgen INC. | $786.86 | 2019-2025 | Uplizna |
| Akcea Therapeutics, INC. | $639.36 | 2019-2021 | |
| Genzyme Corporation | $591.52 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $576.64 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $563.96 | 2019-2024 | Ultomiris, Soliris |
| Horizon Therapeutics Plc | $463.92 | 2021-2023 | Uplizna |
| Harmony Biosciences LLC | $431.42 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $426.66 | 2022 | |
| Sumitomo Pharma America, INC. | $385.35 | 2023-2024 | Aptiom |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.